{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "For the Degree Program Segment:\n- Adjusted EBITDA increased from $180,727 thousand in 2022 to $214,699 thousand in 2023, a change of $33,972 thousand or 18.8%.\n\nFor the Alternative Credential Segment:\n- Adjusted EBITDA increased from $(55,646) thousand in 2022 to $(43,903) thousand in 2023, a change of $11,743 thousand or 21.1%.\n\nFor total segment profitability:\n- Adjusted EBITDA increased from $125,081 thousand in 2022 to $170,796 thousand in 2023, a change of $45,715 thousand or 36.5%.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "From 2022 to 2023:\n\n- Degree Program Segment: \n  - 2022 - $192,459 million of goodwill\n  - 2023 - $192,459 million of goodwill (no change)\n\n- Alternative Credential Segment: \n  - 2022 - $691,531 million of goodwill\n  - 2023 - $659,039 million of goodwill (reduction of $32,492 million)\n\nThe Alternative Credential Segment saw a significant impairment charge in 2022 ($79.471 million), but no impairment charge in 2023, resulting in a lower goodwill balance. The Degree Program Segment remained unchanged.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "From 2022 to 2023:\n\n- Degree Program Segment: FCE enrollments decreased by 39,061, or 16.7%.\n- Alternative Credential Segment: FCE enrollments decreased by 5,825, or 1.5%. (Calculated as (93,471 - 97,647) = -5,825, which is a 1.5% decrease from 2022 to 2023 based on 2022 FCE enrollments of 3,934,140)", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 were:\n\n1. Divestitures - Decreased product revenue by $33.5 million\n2. Lower sales volumes in the dental market\n3. Inflationary cost pressures\n\nThese factors collectively led to a $49.5 million decrease in gross profit from 42.8% margin in 2021 to 39.8% in 2022.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "From 2021 to 2022:\n\n- Property and equipment impairment charges decreased from $788 to $18\n- Intangible assets amortization expense decreased from $15,810 to $15,480", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "From 2021 to 2022:\n- Healthcare Solutions segment operating income decreased from $69,358 to $25,812\n- Industrial Solutions segment operating income decreased from $66,392 to $72,954 (note the order is reversed in the statement)\n\nSo both segments saw a decrease in operating income from 2021 to 2022, but the Healthcare Solutions segment saw a more significant decrease.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds. This was a significant increase compared to $0 million in both 2022 and 2021.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure to move the BNPL platform business activities and management fully under the Cash App segment. This change resulted in the BNPL platform's financial results being included solely within the Cash App segment, rather than being allocated between Square and Cash App as they had been historically.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "From January 31, 2022 to December 31, 2023:\n\n- Consumer receivables were classified as held for investment.\n- The allowance for credit losses related to consumer receivables was $185.3 million as of December 31, 2023.\n\nSpecifically:\n- At December 31, 2022, consumer receivables were $1.871 million and the allowance for credit losses was $151.290 million.\n- At December 31, 2023, consumer receivables were $2.445 million and the allowance for credit losses increased to $185.3 million.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The net property and equipment values decreased by 9.6% from December 31, 2022, to December 31, 2023. Specifically:\n\n2023: $144,718 thousand\n2022: $159,432 thousand\n\nThe decrease is calculated as:\n((159,432 - 144,718) / 159,432) * 100 = -9.6%", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The primary factors affecting C.H. Robinson's financial performance in 2023 were:\n\n1. Weak freight demand and excess carrier capacity in transportation markets, leading to suppressed freight rates.\n\n2. Declines in adjusted gross profits per transaction in truckload and ocean services.\n\n3. Lower volumes in nearly all transportation services.\n\n4. Cost optimization efforts and lower variable compensation reducing personnel expenses.\n\n5. Reduced capital expenditures.\n\n6. Foreign exchange rate fluctuations impacting results.\n\n7. Market conditions resulting in declining transportation rates compared to prior years.\n\nOverall, the soft market conditions and macroeconomic factors had a significant adverse impact on revenues, margins, and profitability in 2023.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "From December 31, 2022, to December 31, 2023:\n\n- In 2022, the Company recorded revenue of $257.6 million for services provided while shipments were in-transit but not yet completed or invoiced.\n- In 2023, the Company recorded revenue of $189.9 million for similar services.\n\nThis indicates a decline in the revenue recognized for in-transit shipments, primarily due to macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "For the year ended December 31, 2023, the total stock-based compensation expense was $231,312 thousand. As of December 31, 2023, the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was $354,800 thousand, which is approximately $123.5 million more than the stock-based compensation expense for the year.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "From 2022 to 2023:\n\n- Research and development expenses increased by $32.5 million to $425.9 million.\n- Sales and marketing expenses decreased by $118.9 million to $727.1 million.\n\nThe main reasons for these changes were:\n\n- R&D expenses grew due to increased personnel expenses ($37.0 million) and facility and support services ($18.6 million), particularly for MCED and MRD research activities.\n- Sales and marketing expenses decreased due to lower direct marketing costs and professional fees, reduced overlap in the sales force, and fewer costs on commercial IT projects.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporationâ€™s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "Exact Sciences Corporation's cash and cash equivalents increased from $242,493 thousand at the beginning of 2023 to $605,378 thousand at the end of 2023. This increase was primarily due to:\n\n1. Operating activities generating $156,119 thousand in cash.\n2. Investing activities using $139,854 thousand for purchases of marketable securities, but also generating $363,156 thousand from maturities and sales of marketable securities.\n3. Financing activities providing $159,766 thousand through proceeds from the issuance of convertible notes and the company's employee stock purchase plan.\n\nThe net increase was $366,885 thousand, resulting in the year-end balance of $609,675 thousand.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "From 2022 to 2023:\n\n- Net product sales increased by $22.4 million, from $55.9 million to $78.3 million.\n- Collaboration revenue increased by $18.4 million, from $19.6 million to $37.999 million.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233.659 million in 2022 to $209.248 million in 2023. The factors contributing to this change include:\n\n1. Increased product sales: Net product sales rose from $55.9 million in 2022 to $78.3 million in 2023.\n\n2. Higher collaboration revenue: This increased from $19.6 million in 2022 to $37.999 million in 2023.\n\n3. Decreased research and development expenses: These fell from $118.927 million in 2022 to $86.107 million in 2023, primarily due to reduced costs related to the CLEAR Outcomes study after announcing and presenting its results in 2023.\n\n4. Increased selling, general, and administrative expenses: These went up from $109.922 million in 2022 to $142.523 million in 2023, mainly due to increased legal costs, headcount, and promotional expenses.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "From 2022 to 2023:\n\n- Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million to $78.3 million.\n- Collaboration revenue increased from $19.6 million to $37.999 million.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "From 2021 to 2023:\n- Property & Casualty insurance revenue decreased by 26.8% (from $224,366 million to $164,234 million)\n- Health insurance revenue decreased by 0.6% (from $187,392 million to $186,275 million)\n\nSo the Property & Casualty insurance vertical saw a larger percentage decrease (-26.8%) compared to the Health insurance vertical (-0.6%) from 2021 to 2023.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In the year ended December 31, 2023:\n\n- Open Marketplace transactions revenue: $378,730 million\n- Private Marketplace transactions revenue: $9,419 thousand\n\nOpen Marketplace transactions accounted for 97.4% of total revenue ($388,149 million), while Private Marketplace transactions made up a smaller portion.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue for the year ended December 31, 2023, compared to 2022, was due primarily to a decrease in customer acquisition spending by P&C carriers in response to lower than expected underwriting profitability. This significant reduction in spending by P&C carriers led to a $144.1 million decrease in Transaction Value and a $70.9% decline in total revenue for the P&C insurance vertical, contributing to the overall $70.923 million or 15.4% decrease in total revenue from $459.072 million in 2022 to $388.149 million in 2023.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Regulatory changes in the EU could:\n\n1. Reduce data exclusivity from 8 years to 6 years.\n2. Introduce additional data protection requirements for new medical therapies.\n3. Impact the regulation of medical devices containing medicinal products.\n4. Require additional clinical data or post-market surveillance for product approvals.\n5. Increase costs and complexity of clinical trials and product launches.\n6. Potentially limit market entry for new products.\n7. Require changes to product development and commercialization strategies.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "Between December 31, 2022, and December 31, 2023, the company did not issue any of the equity securities registered under the shelf registration statement. As of December 31, 2023, $99.8 million remained available for issuance under the shelf registration statement, of which $59.8 million is reserved for sales under the ATM program.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "If the company fails to comply with controlled substance laws and regulations:\n\n1. It may face significant fines, penalties, and administrative sanctions.\n2. Convictions could result in imprisonment.\n3. It could be forced to cease business activities or divest itself.\n4. Its products may be seized or detained.\n5. It may be excluded from participation in government healthcare programs\n6. It could experience delays or denials in obtaining marketing approvals\n7. It might be required to recall or remove products from the market\n8. It could be subject to criminal prosecution\n9. Reputational damage could occur, harming its business prospects and market acceptance.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "A single customer within the Compute & Networking segment represented 13% of total revenue for fiscal year 2024. This concentration poses challenges such as:\n\n1. Increased risk of losing a significant revenue source if customer relationships are strained.\n2. Potential supply chain disruptions if this customer faces issues.\n3. Vulnerability to changes in this customer's business strategy or financial situation.\n4. Difficulty in predicting demand and managing supply chain given the customer's influence.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "NVIDIA's net income increased from $4,368 million in fiscal year 2023 to $29,760 million in fiscal year 2024, a change of +2,539.2%. Revenue increased from $26,974 million to $60,922 million, a change of +126%.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "13% of total revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment. This demonstrates the risk presented in the Risk Factors that \"The loss of any of our large customers, a significant reduction in purchases by them, our inability to sell to a customer due to U.S. or other countries' trade restrictions or any difficulties in collecting accounts receivable would likely harm our financial condition and results of operations.\"", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": false, "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": false, "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": false, "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "From 2022 to 2023:\n\n- Automotive sales revenue increased by $11.30 billion (17%) to $82,419 million.\n- Gross margin decreased from 28.5% to 19.4%.\nKey factors:\n1. Increase in deliveries, particularly Model Y globally.\n2. Lower average selling price due to overall price reductions, sales mix, and currency impacts.\n3. Favorable changes in cost per unit, including lower inbound freight, material costs, and manufacturing costs.\n4. Impact of U.S. dollar strengthening against other foreign currencies.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "From December 31, 2022, to December 31, 2023:\n\n- Short-term investments increased from $4,859 million to $6,996 million\n- Inventory increased from $12,839 million to $13,626 million", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "For New York:\n- Required to spend $5.00 billion in combined capital, operational expenses, etc. by December 31, 2029\n- Must meet employment targets and personnel minimums\n\nFor Shanghai:\n- Required to spend RMB 14.08 billion in capital expenditures by end of 2023 (achieved in 2023)\n- Must generate RMB 2.23 billion in annual tax revenues starting in 2023 (met as of December 31, 2023)\n\nSo New York has ongoing long-term commitments for spending and employment, while Shanghai had a one-time capital expenditure requirement that was met, with an ongoing tax revenue requirement.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
